Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413809 | 0.83 | ALOX12 (0.36) | CA2ALOX12ALDH1A1GABRA1GABRB2 | |
| SCHEMBL2489642 | 0.81 | CA2 (0.58) | CA2CA1ALOX12SRCMEN1 | |
| SCHEMBL5383978 | 0.81 | CA1 (0.39) | CA2CA1SRCTDP1ERN1 | |
| SCHEMBL1620557 | 0.81 | CA1 (0.39) | CA2CA1SRCTDP1ERN1 | |
| SCHEMBL4271982 | 0.80 | ALOX12 (0.36) | CA2ALOX12TDP1ALDH1A1TSHR | |
| SCHEMBL180679 | 0.79 | CA2 (0.43) | CA2CA1ALOX12SRCMEN1 | |
| SCHEMBL1620797 | 0.77 | ALDH1A1 (0.34) | LMNAALDH1A1 | |
| Methyl Alcohol SCHEMBL28273000 | 0.77 | CA2 (0.45) | CA2CA1ALOX12SRCMEN1 | |
| SCHEMBL1728866 | 0.75 | PIM1 (0.44) | CA2CA1ALOX12SRCMEN1 | |
| SCHEMBL1254406 | 0.75 | ALDH1A1 (0.41) | CA2CA1ALOX12SRCERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107235883-B | Diaryl-beta-lactam compound, preparation method thereof and application thereof in pharmacy | 复旦大学 | 2021-06-29 | — | — | CN | disclosed |
| CN-112313221-A | Cannabinoid derivatives and conjugates and uses thereof | 比托邦制药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| CN-100425594-C | PPAR activating compound and pharmaceutical composition containing the same | KOWA CO (JP) | 2008-10-15 | — | — | CN | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| CN-1845905-A | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO (JP) | 2006-10-11 | — | — | CN | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128667-A1 | Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators | MONTES IMBER F | 2006-06-15 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1504013-A4 | HYDROXYPHOSPHONATES AND PHOSPHONOPHOSPHATES AS APOLIPOPROTEIN E MODULATORS | ILEX PRODUCTS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1504013-A2 | HYDROXYPHOSPHONATES AND PHOSPHONOPHOSPHATES AS APOLIPOPROTEIN E MODULATORS | Ilex Products, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003094852-A2 | HYDROXYPHOSPHONATES AND PHOSPHONOPHOSPHATES AS APOLIPOPROTEIN E MODULATORS | ILEX PRODUCTS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128667-A1 | Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators | APOB, APOL1, PPME1 | CA2 4169/4885CA1 4328/4885ALOX12 655/4885 |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | CA2 3278/4885CA1 4693/4885ALOX12 341/4885 |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARG, PPARA, PPARD | CA2 3179/4885CA1 4695/4885ALOX12 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.